

Insights to Manage Renal Cell Carcinoma with First-line Immuno-oncology/Tyrosine Kinase Inhibitor Combination Therapies: WHICH OF YOUR PATIENTS CAN BENEFIT?

Arjun V. Balar, MD
Associate Professor Medicine
Director, Genitourinary Medical Oncology Program
Laura and Isaac Perlmutter Cancer Center
NYU Langone Health
New York, NY

